1,124
Views
1
CrossRef citations to date
0
Altmetric
Research Paper

Discovery of novel thiosemicarbazone derivatives with potent and selective anti-Candida glabrata activity

, , , , &
Article: 2202362 | Received 20 Feb 2023, Accepted 08 Apr 2023, Published online: 20 Apr 2023

References

  • Bitar D, Lortholary O, Le Strat Y, Nicolau J, Coignard B, Tattevin P, Che D, Dromer F. Population-based analysis of invasive fungal infections, France, 2001–2010. Emerg Infect Dis. 2014;20(7):1149–1155.
  • Arendrup MC, Patterson TF. Multidrug-resistant candida: epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017;216(suppl_3):S445–S451.
  • Barantsevich N, Barantsevich E. Diagnosis and treatment of invasive candidiasis. Antibiotics . 2022;11(6):718.
  • Kumar S, Kumar A, Roudbary M, Mohammadi R, Černáková L, Rodrigues CF. Overview on the infections related to rare candida species. Pathogens. 2022;11(9):963.
  • Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J. Candida glabrata, candida parapsilosis and candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol Rev. 2012;36(2):288–305.
  • Frías-De-León MG, Hernández-Castro R, Conde-Cuevas E, García-Coronel IH, Vázquez-Aceituno VA, Soriano-Ursúa MA, Farfán-García ED, Ocharán-Hernández E, Rodríguez-Cerdeira C, Arenas R, et al. Candida glabrata antifungal resistance and virulence factors, a perfect pathogenic combination. Pharmaceutics. 2021;13(10):1529.
  • Rodrigues CF, Silva S, Henriques M. Candida glabrata: a review of its features and resistance. Eur J Clin Microbiol Infect Dis. 2014;33(5):673–688.
  • Colombo AL, Junior JNA, Guinea J. Emerging multidrug-resistant candida species. Curr Opin Infect Dis. 2017;30(6):528–538.
  • Csank C, Haynes K. Candida glabrata displays pseudohyphal growth. FEMS Microbiol Lett. 2000;189(1):115–120.
  • Zheng Q, Liu J, Qin J, Wang B, Bing J, Du H, Li M, Yu F, Huang G. Ploidy variation and spontaneous haploid-diploid switching of candida glabrata clinical isolates. mSphere 2022:e0026022.
  • Robbins N, Caplan T, Cowen LE. Molecular evolution of antifungal drug resistance. Annu Rev Microbiol. 2017;71:753–775.
  • Lee Y, Puumala E, Robbins N, Cowen LE. Antifungal drug resistance: molecular mechanisms in candida albicans and beyond. Chem Rev. 2021;121(6):3390–3411.
  • Arendrup MC, Perlin DS. Echinocandin resistance: an emerging clinical problem? Curr Opin Infect Dis. 2014;27(6):484–492.
  • Lee A. Ibrexafungerp: first approval. Drugs. 2021;81(12):1445–1450.
  • Li L, Wu H, Zhu S, Ji Z, Chi X, Xie F, Hao Y, Lu H, Yang F, Yan L, et al. Discovery of novel 7-hydroxy-5-oxo-4,5-dihydrothieno[3,2-b]pyridine-6-carboxamide derivatives with potent and selective antifungal activity against cryptococcus species. J Med Chem. 2022;65(16):11257–11269.
  • Lv Q, Ni T, Li L, Li T, Zhang D, Jiang Y. A new antifungal agent (4-phenyl-1, 3-thiazol-2-yl) hydrazine induces oxidative damage in candida albicans. Front Cell Infect Microbiol. 2020;10:578956.
  • Ni T, Xie F, Li L, Hao Y, Chi X, Yan L, Zhang D, Jiang Y, Lv Q. Design, synthesis and structure-activity relationship studies of nicotinamide derivatives as potent antifungal agents by disrupting cell wall. Molecules. 2023;28(3):1135.
  • Wang Y, Gu W, Shan Y, Liu F, Xu X, Yang Y, Zhang Q, Zhang Y, Kuang H, Wang Z, et al. Design, synthesis and anticancer activity of novel nopinone-based thiosemicarbazone derivatives. Bioorg Med Chem Lett. 2017;27(11):2360–2363.
  • Bal TR, Anand B, Yogeeswari P, Sriram D. Synthesis and evaluation of anti-hiv activity of isatin beta-thiosemicarbazone derivatives. Bioorg Med Chem Lett. 2005;15(20):4451–4455.
  • Liu L, Xu YS, Chigan JZ, Zhai L, Ding HH, Wu XR, Chen WY, Yang KW. Dihydroxyphenyl-substituted thiosemicarbazone: a potent scaffold for the development of metallo-beta-lactamases inhibitors and antimicrobial. Bioorg Chem. 2022;127:105928.
  • Muğlu H, Çavuş MS, Bakır TK, Yakan H. Synthesis of new bis(thiosemicarbazone) derivatives and dft analysis of antioxidant characteristics in relation to hat and set reactions. J Indian Chem Soc. 2022;99(12):100789.
  • Rahim F, Ullah H, Taha M, Hussain R, Sarfraz M, Iqbal R, Iqbal N, Khan S, Ali Shah SA, Albalawi MA, et al. Synthesis of new triazole-based thiosemicarbazone derivatives as anti-alzheimer’s disease candidates: evidence-based in vitro study. Molecules. 2023;28(1):21.
  • Singh P, Rawat S, Agrahari AK, Singh M, Chugh S, Gurcha S, Singh A, Abrahams K, Besra GS, Asthana S, et al. Nsc19723, a thiacetazone-like benzaldehyde thiosemicarbazone improves the efficacy of tb drugs in vitro and in vivo. Microbiol Spectr. 2022;10(6):e02592–22.
  • de Oliveira RB, de Souza-Fagundes EM, Soares RP, Andrade AA, Krettli AU, Zani CL. Synthesis and antimalarial activity of semicarbazone and thiosemicarbazone derivatives. Eur J Med Chem. 2008;43(9):1983–1988.
  • de Araujo Neto LN, de Lima M, de Oliveira JF, de Souza ER, Feitosa Machado SE, de Souza Lima GM, Silva Buonafina MD, Brayner FA, Alves LC, Sandes JM, et al. Thiophene-thiosemicarbazone derivative (l10) exerts antifungal activity mediated by oxidative stress and apoptosis in c. Albicans. Chem Biol Interact. 2020;320:109028.
  • Baell JB, Ferrins L, Falk H, Nikolakopoulos G. Pains: relevance to tool compound discovery and fragment-based screening. Aust J Chem. 2013;66(12):1483–1494.
  • Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (pains) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010;53(7):2719–2740.
  • CLSI. Reference method for broth dilution antifungal suscepti bility testing of yeasts, m27-a3, third ed., Wayne: Clinical and Laboratory Standards Institute pa 2009.
  • CLSI. Performance standards for antifungal susceptibility testing of yeast, m60, first ed., Wayne: Clinical and Laboratory Standards Institute, pa. 2017.
  • Widiasih Widiyanto T, Chen X, Iwatani S, Chibana H, Kajiwara S. Role of major facilitator superfamily transporter qdr2p in biofilm formation by candida glabrata. Mycoses. 2019;62(12):1154–1163.
  • Fidel PL, Jr., Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to c. Albicans. Clin Microbiol Rev. 1999;12(1):80–96.
  • Daina A, Michielin O, Zoete V. Swissadme: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717.
  • Li DD, Zhao LX, Mylonakis E, Hu GH, Zou Y, Huang TK, Yan L, Wang Y, Jiang YY. In vitro and in vivo activities of pterostilbene against candida albicans biofilms. Antimicrob Agents Chemother. 2014;58(4):2344–2355.
  • Lu R, Ni T, Wu J, Yan L, Lv Q, Li L, Zhang D, Jiang Y. New triazole nt-a9 has potent antifungal efficacy against cryptococcus neoformans in vitro and in vivo. Antimicrob Agents Chemother. 2020;64(2):e01628-01619.
  • Li L, Zhang T, Xu J, Wu J, Wang Y, Qiu X, Zhang Y, Hou W, Yan L, An M, et al. The synergism of the small molecule enoblock and fluconazole against fluconazole-resistant candida albicans. Front Microbiol. 2019;10(:2071.